AR Moschen

AR Moschen

Medizinische Universität Innsbruck

H-index: 60

Europe-Austria

About AR Moschen

AR Moschen, With an exceptional h-index of 60 and a recent h-index of 46 (since 2020), a distinguished researcher at Medizinische Universität Innsbruck, specializes in the field of gastroenterology, mucosal immunology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Gut microbiome, obesity, and metabolic syndrome

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

P809 VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and …

P905 Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib-First results from the IBD-DACH study EUROPE

Prediction of response to systemic corticosteroids in active UC by microbial composition—a prospective multicenter study

Kasuistik: Behandlung einer chronischen Hepatitis C mittels DAA bei einem Patienten mit Kurzdarmsyndrom

B and T Cell Responses to SARS-CoV-2 Vaccination in Kidney and Liver Transplant Recipients with and without Previous COVID-19

Leitfaden Kurzdarmsyndrom

AR Moschen Information

University

Medizinische Universität Innsbruck

Position

Professor of Medicine

Citations(all)

24227

Citations(since 2020)

10985

Cited By

17262

hIndex(all)

60

hIndex(since 2020)

46

i10Index(all)

101

i10Index(since 2020)

87

Email

University Profile Page

Medizinische Universität Innsbruck

AR Moschen Skills & Research Interests

gastroenterology

mucosal immunology

Top articles of AR Moschen

Title

Journal

Author(s)

Publication Date

Gut microbiome, obesity, and metabolic syndrome

Herbert Tilg

Alexander R Moschen

2024/1/31

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

Journal of Crohn's and Colitis

S Reider

C Watschinger

R Koch

H Tilg

A Moschen

2024/1/1

P809 VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and …

Journal of Crohn's and Colitis

G Novacek

P Hrúz

C Högenauer

E Louis

SR Vavricka

...

2024/1/1

P905 Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib-First results from the IBD-DACH study EUROPE

Journal of Crohn's and Colitis

S Zeissig

R Schmelz

U Helwig

AR Moschen

T Greuter

...

2024/1/1

Prediction of response to systemic corticosteroids in active UC by microbial composition—a prospective multicenter study

Inflammatory Bowel Diseases

Andreas Blesl

Philipp Wurm

Silvio Waschina

Hans Peter Gröchenig

Gottfried Novacek

...

2024/1/1

Kasuistik: Behandlung einer chronischen Hepatitis C mittels DAA bei einem Patienten mit Kurzdarmsyndrom

Zeitschrift für Gastroenterologie

N Loschko

A Moschen

2023/5

B and T Cell Responses to SARS-CoV-2 Vaccination in Kidney and Liver Transplant Recipients with and without Previous COVID-19

Viruses

Christina Watschinger

Gerald Stampfel

Andreas Zollner

Anna M Hoog

Annika Rössler

...

2023/12/19

Leitfaden Kurzdarmsyndrom

Zeitschrift für Gastroenterologie

S Dabsch

F Harpain

E Hütterer

L Kramer

N Loschko

...

2023/5

Use of subcutaneous Vedolizumab: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH)

Zeitschrift fur Gastroenterologie

Simon Reider

Gottfried Novacek

Thomas Haas

Hans-Peter Gröchenig

Reingard Platzer

...

2023/11

Consensus Statement der Österreichischen Gesellschaften für Rheumatologie und Rehabilitation, Pneumologie, Infektiologie, Dermatologie und Gastroenterologie zum Umgang mit …

Eva Rath

Michael Bonelli

Christina Duftner

Johann Gruber

Peter Mandl

...

2023/3

Positionspapier der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der ÖGGH zum Einsatz von Vedolizumab subkutan

Zeitschrift für Gastroenterologie

Simon Reider

Gottfried Novacek

Thomas Haas

Hans-Peter Gröchenig

Reingard Platzer

...

2023/11

Reduced SARS-CoV-2 infection and altered antiviral transcriptional response in IBD intestinal organoids.(preprint)

Barbara Jelusic

Stefan Boerno

Philipp Wurm

Nicole Przysiecki

Christina Watschinger

...

2023

Factors Associated with Response to Systemic Corticosteroids in Active Ulcerative Colitis: Results from a Prospective, Multicenter Trial

Journal of Clinical Medicine

Andreas Blesl

Andrea Borenich

Hans Peter Gröchenig

Gottfried Novacek

Christian Primas

...

2023/7/24

Tofacitinib in the treatment of ulcerative colitis: A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and …

Wiener Klinische Wochenschrift

Maximilian Kutschera

Gottfried Novacek

Walter Reinisch

Christoph Högenauer

Wolfgang Petritsch

...

2023/1

A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma

Hepatology Communications

Maria Effenberger

Silvio Waschina

Christina Bronowski

Gregor Sturm

Oronzo Tassiello

...

2023/7/1

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

Intestinal research

Jae Hee Cheon

Kristine Paridaens

Sameer Al Awadhi

Jakob Begun

John R Fullarton

...

2023/1

Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

Scandinavian Journal of Gastroenterology

Axel U Dignass

Kristine Paridaens

Sameer Al Awadhi

Jakob Begun

Jae Hee Cheon

...

2022/4/3

National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent …

Eva Rath

Michael Bonelli

Christina Duftner

Johann Gruber

Peter Mandl

...

2022/11

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

npj Vaccines

Michael Karbiener

Maria R Farcet

Andreas Zollner

Taisei Masuda

Mitsuhiro Mori

...

2022/2/18

Short- and Long-Term Effects of a Prebiotic Intervention with Polyphenols Extracted from European Black Elderberry—Sustained Expansion of Akkermansia spp.

Journal of personalized medicine

Simon Reider

Christina Watschinger

Julia Längle

Ulrike Pachmann

Nicole Przysiecki

...

2022/9/9

See List of Professors in AR Moschen University(Medizinische Universität Innsbruck)

AR Moschen FAQs

What is AR Moschen's h-index at Medizinische Universität Innsbruck?

The h-index of AR Moschen has been 46 since 2020 and 60 in total.

What are AR Moschen's top articles?

The articles with the titles of

Gut microbiome, obesity, and metabolic syndrome

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

P809 VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and …

P905 Symptomatic remission and IUS improvements in a multi-national real-world cohort of UC patients treated with Upadacitinib-First results from the IBD-DACH study EUROPE

Prediction of response to systemic corticosteroids in active UC by microbial composition—a prospective multicenter study

Kasuistik: Behandlung einer chronischen Hepatitis C mittels DAA bei einem Patienten mit Kurzdarmsyndrom

B and T Cell Responses to SARS-CoV-2 Vaccination in Kidney and Liver Transplant Recipients with and without Previous COVID-19

Leitfaden Kurzdarmsyndrom

...

are the top articles of AR Moschen at Medizinische Universität Innsbruck.

What are AR Moschen's research interests?

The research interests of AR Moschen are: gastroenterology, mucosal immunology

What is AR Moschen's total number of citations?

AR Moschen has 24,227 citations in total.

What are the co-authors of AR Moschen?

The co-authors of AR Moschen are Romana R. Gerner.